• Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans

Subscribe to Updates

Get the latest finance news and updates directly to your inbox.

Top News

Big Beautiful Bill Estate Planning Ideas

July 9, 2025

6 Steps to Creating a Home Inventory — Before It’s Too Late

July 9, 2025

Starbucks Wants to Remove Seed Oils From Egg Bites

July 8, 2025
Facebook Twitter Instagram
Trending
  • Big Beautiful Bill Estate Planning Ideas
  • 6 Steps to Creating a Home Inventory — Before It’s Too Late
  • Starbucks Wants to Remove Seed Oils From Egg Bites
  • Barbara Corcoran Retains Staff With Wild Perks, No Turnover
  • How to Turn Summer Travel into More Business and Less Taxes
  • Proposed Law Would Mandate Automatic Enrollment Into Medicare Advantage
  • New Tariff Threats Tank Stocks: Find Out How to Protect Your Portfolio
  • These Jobs Can Pay $100 an Hour (or More) Without a Degree
Wednesday, July 9
Facebook Twitter Instagram
FintechoPro
Subscribe For Alerts
  • Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans
FintechoPro
Home » Novo Nordisk’s Production Capacity in Focus With Earnings Set to Soar — Earnings Preview
Investing

Novo Nordisk’s Production Capacity in Focus With Earnings Set to Soar — Earnings Preview

News RoomBy News RoomAugust 10, 20230 Views0
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email Tumblr Telegram

By Dominic Chopping

Novo Nordisk is scheduled to report results for the second quarter on Thursday. Here’s what to watch:

NET PROFIT FORECAST: Net profit in the quarter is seen rising 55% to 20.63 billion Danish kroner ($3.03 billion), according to a FactSet poll of analysts.

SALES FORECAST: A FactSet poll sees second-quarter sales rising to DKK55.47 billion from DKK41.27 billion last year.

WHAT TO WATCH:

–GLP-1 DRUGS: Sydbank senior analyst Soren Lontoft Hansen said in a note that he expects Novo Nordisk’s glucagon-like peptide-1 drugs, or GLP-1, for treating type 2 diabetes and obesity to have continued their strong growth in the quarter, modeling overall sales growth of 43% on the year for GLP-1 diabetes treatments to DKK27.45 billion. Temporary production challenges in several markets as a result of high demand may dampen the growth picture somewhat, he says. The Danish pharmaceutical company’s Ozempic diabetes drug is also being used to treat obesity “off-label” and Sydbank expects Ozempic sales grew 44% on year. Prescription data from the U.S. shows continued extremely high demand for obesity drug Wegovy, but Novo Nordisk’s previous decision to reduce the supply of low doses in the U.S. will eat into quarterly growth, he adds. Hansen models Wegovy sales of DKK5.56 billion. Both Ozempic and Wegovy are based on the same active ingredient – semaglutide. Novo Nordisk on Tuesday said a trial of Wegovy showed that it not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20%.

–MARGINS: Sydbank expects the gross margin to be helped by the marked increase in sales and product-mix effects, while lower net prices in the U.S. and currency effects pull in the opposite direction. The bank models a gross margin of 84.0% from 85.3% last year. “We see rising capacity costs in the form of higher costs for research and development as well as sales and distribution in the quarter, which reflects the higher level of activity. However, in our estimation, the increase in capacity costs will be less than the top line growth.”

–GUIDANCE: The company expects 2023 sales growth of 24% to 30% on year and operating profit growth of 28% to 34% in constant currencies. Reported growth in sales is seen around six percentage points below constant currencies, while reported operating profit growth is seen around nine percentage points lower. Sydbank thinks that production challenges for the GLP-1 portfolio within diabetes and obesity treatment may put a damper on an upward adjustment to guidance. “Novo Nordisk’s production capacity will therefore be on the focus list in connection with the accounts.”

Write to Dominic Chopping at [email protected]

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

Barbara Corcoran Retains Staff With Wild Perks, No Turnover

Investing July 8, 2025

Jack Dorsey Announces Bitchat Messaging App

Investing July 7, 2025

101 Small Business Ideas to Match Your Personality, Investment, Skills & Goals

Investing July 6, 2025

How to Deal With Negative Articles on Google

Investing July 5, 2025

13 Jobs Without College or AI: Salaries Can Start at $70k+

Investing July 2, 2025

Why Your Finance Team Needs an AI Strategy, Now

Investing July 1, 2025
Add A Comment

Leave A Reply Cancel Reply

Demo
Top News

6 Steps to Creating a Home Inventory — Before It’s Too Late

July 9, 20250 Views

Starbucks Wants to Remove Seed Oils From Egg Bites

July 8, 20250 Views

Barbara Corcoran Retains Staff With Wild Perks, No Turnover

July 8, 20250 Views

How to Turn Summer Travel into More Business and Less Taxes

July 8, 20250 Views
Don't Miss

Proposed Law Would Mandate Automatic Enrollment Into Medicare Advantage

By News RoomJuly 8, 2025

“H.R. 3467, To amend title XVIII to reform the Medicare Advantage program,” was introduced on…

New Tariff Threats Tank Stocks: Find Out How to Protect Your Portfolio

July 8, 2025

These Jobs Can Pay $100 an Hour (or More) Without a Degree

July 8, 2025

Being ‘Nice’ Almost Cost Me My Business — Here’s What I Do Differently Now

July 7, 2025
Facebook Twitter Instagram Pinterest Dribbble
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 FintechoPro. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.